Regeneron joins Lilly in validating the Covid antibody approach
Like Lilly Regeneron reports promising but not emphatic data with its antibody treatment, and the question turns to approvability.
Lilly leads the Covid antibody charge
LY-CoV555 shows promising signs for the antibody approach, with Regeneron not far behind.
Amgen and Astra hope to carve out a place in asthma
Pivotal data are expected soon on tezepelumab, Amgen and Astrazeneca's shot at non-eosinophilic asthma.
A poor quarter for Roche leads to muted expectations
Launching a suite of Covid-19 diagnostics could not prevent Roche’s first-half profits sliding 5%.
